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Original Article
Treatment Response in Depressed Adolescents
With and Without Co-Morbid Attention-Deficit=Hyperactivity
Disorder in the Treatment for Adolescents
with Depression Study
Christopher J. Kratochvil, M.D.,1 Diane E. May, M.S.N., M.A.,1 Susan G. Silva, Ph.D.,2
Vishal Madaan, M.D.,1 Susan E. Puumala, M.S.,1 John F. Curry, Ph.D.,2 John Walkup, M.D.,3
Hayden Kepley, Ph.D.,4 Benedetto Vitiello, M.D.,5 and John S. March, M.D.2
Abstract
Objective: In the Treatment for Adolescents with Depression Study (TADS), fluoxetine (FLX) and the combination of
fluoxetine with cognitive-behavioral therapy (COMB) had superior improvement trajectories compared to pill placebo
(PBO), whereas cognitive–behavioral therapy (CBT) was not significantly different from PBO. Because attention-deficit=
hyperactivity disorder (ADHD) and major depressive disorder (MDD) frequently co-exist, we examined whether ADHD
moderated these outcomes in TADS.
Method: A total of 439 adolescents with MDD, 12–17 years old, were randomized to FLX, CBT, COMB, or PBO. Random
coefficients regression models examined depression improvement in 377 depressed youths without ADHD and 62 with
ADHD, including 20 who were treated with a psychostimulant.
Results: Within the ADHD group, the improvement trajectories of the three active treatments were similar, all with rates
of improvement greater than PBO. For those without ADHD, only COMB had a rate of improvement that was superior to
PBO.
Conclusions:Co-morbidADHDmoderated treatment ofMDD.CBTalone or FLXalonemay offer benefits similar toCOMB
in the treatment of MDD in youths with co-morbid MDD and ADHD, whereas monotherapy may not match the benefits of
COMB for thosewithout ADHD. TheADHD subgroup analysis presented in this paper is exploratory in nature because of the
small number of youths with ADHD in the sample.
Clinical Trial Registry:www.clinicaltrials.gov Identifier: NCT00006286. The TADS protocol and all of the TADSmanuals
are available on the Internet at https:==trialweb.dcri.duke.edu=tads=index.html.
Introduction
A
ttention-deficit=hyperactivity disorder (ADHD) and
depressive disorders are common in the pediatric population,
with as many as 20–30% of children and adolescents diagnosed
with ADHD concurrently experiencing a depressive disorder
(Anderson et al. 1987; Biederman et al. 1991; American Psychiatric
Association 1994; Angold et al. 1999). Studies by Biederman et al.
have demonstrated that adolescents with ADHD have a 2.5 times
higher risk for major depressive disorder (MDD) than those
without ADHD (Biederman et al. 2008). Because each disorder
independently can lead to significant functional impairment, the
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frequency and impact of simultaneously experiencing the combi-
nation of MDD and ADHD is clearly of great clinical concern.
To date, there is a lack of strong evidence supporting a single
treatment for co-morbid MDD and ADHD in adolescents. Of the
available pharmacological treatments, tricyclic norepinephrine re-
uptake inhibitors (e.g., desipramine, nortriptyline) have been
shown to improve symptoms of ADHD in pediatric populations and
depression in adults. The use of these inhibitors in adolescents has
been limited by safety and tolerability concerns, and their efficacy
as antidepressants has not been well established in this population
(Biederman et al. 1993; Wilens et al. 1993; Geller et al. 1999;
Prince et al. 2000). Selective serotonin reuptake inhibitors (SSRIs)
have demonstrated benefits in adolescent depression and are as-
sociated with fewer adverse effects and reduced overdose toxicity,
as compared to tricyclic antidepressants, but there is little evidence
of efficacy in ADHD (Barrickman 1991; Goldstein and Goodnick
1998; Quintana et al. 2007). Studies have also examined the use of
atomoxetine in co-morbid youths. An open-label study of children
and adolescents found that atomoxetine, alone or in combination
with fluoxetine, improved symptoms of ADHD and depressive
symptoms (Kratochvil et al. 2005). However, in a later double-
blind, placebo-controlled study, atomoxetine improved ADHD
symptoms, but did not significantly differ from placebo in im-
proving depressive symptoms (Atomoxetine ADHD and Comorbid
MDD Study Group et al. 2007). In an open-label trial of bupropion
sustained-release, 14 of 24 adolescents were rated as respond-
ers in both depression and ADHD, providing data supportive of
further placebo-controlled studies of bupropion (Daviss et al.
2001).
Combination pharmacological treatments, such as use of an
SSRI along with a stimulant have not been well studied, other than
an open-label study using a sample of adults and adolescents with
ADHD. This study demonstrated that further global improvements
were achieved in attention, behavior, and affect when methylphe-
nidate (MPH) was added to either fluoxetine or sertraline (Findling
1996; Stoll et al. 1996). To date, no large randomized trials have
investigated combinational pharmacological treatments of co-
morbid ADHD and MDD.
Nonpharmacological treatments, such as cognitive–behavioral
therapy (CBT) and interpersonal therapy (IPT), have been shown to
be moderately effective in the treatment of depressed adolescents
(Birmaher et al. 1996; Reinecke et al. 1998; Lewinsohn et al. 1999;
Mufson and Sills 2006). Although several studies have suggested
that CBT may be helpful in decreasing functional impairment in
depressed adolescents, large controlled studies of CBT that are
specific to adolescents with co-morbid ADHD and MDD have not
been conducted (Antshel and Barkley 2008).
The Treatment for Adolescents with Depression Study (TADS)
was a clinical trial of 439 depressed adolescents that compared the
effectiveness of four randomized treatments: Pharmacotherapy
with fluoxetine (FLX), CBT, the combination of FLX plus CBT
(COMB), and clinical management with pill placebo (PBO). Be-
cause half of the adolescents in TADS met criteria for at least one
co-morbid psychiatric disorder at baseline, the study provided an
opportunity to examine the impact that having a co-morbid diag-
nosis of ADHD had on the outcome of treatment in depressed
adolescents who participated in TADS. Given the high level of
impairment that may result from ADHD alone, we hypothesized
that TADS participants with co-morbid ADHDwould be less likely
to respond or would respond differentially to TADS treatment
across: (1) The 12-week blinded portion of the study, and (2) the
entire 36-week treatment period. Our secondary hypotheses are
based on past literature of samples of youths with co-morbid
ADHD and MDD. We expected that, at baseline, TADS partici-
pants with ADHD would have a greater severity of MDD symp-
toms, a higher level of global impairment, and increased suicidality
in comparison to participants without ADHD. Additionally, we
expected that TADS participants with ADHD, as compared to those
without ADHD, would be more likely to prematurely terminate
treatment and drop out of the study.
Methods
TADS sample and design
The rationale, design, methods, and sample characteristics of
TADS (TADS 2003; TADS 2005), along with the 12-week acute
treatment (TADS 2004) and the overall 36-week treatment out-
comes (TADS 2007), have been described in great detail in prior
publications. Only those aspects of the study that are directly rel-
evant to these analyses will be presented. In summary, TADS was a
publicly funded, randomized controlled trial (RCT) conducted
between 2000 and 2003 to evaluate the 12-week and 36-week
outcomes of four treatments for MDD: FLX (n¼ 109), CBT
(n¼ 111), COMB (n¼ 107), and PBO (n¼ 112). PBOwas included
as a control only during the first 12 weeks of treatment. TADS
enrolled 439 adolescents, ages 12–17 years, including 54.4% fe-
males and 74.8% Caucasians. Adolescents were excluded if they
were considered to be at especially high risk for suicide, as evi-
denced by a recent history of suicidal behavior or prominent sui-
cidal ideation, or if they had co-morbid substance abuse, bipolar
disorder, severe conduct disorder, thought disorder, or were deemed
at ‘‘high-risk’’ for self-injurious or aggressive acts (TADS 2003).
After 12 weeks of acute treatment, the two blinded pharmaco-
therapy treatments (PBO, FLX) were unblinded and PBO treatment
was discontinued regardless of response. Youths who were ran-
domized to an active treatment (FLX, CBT, COMB) and had at
least partial improvement in symptom severity continued their
randomized treatment for 24 additional weeks.
TADS was somewhat unique among pediatric MDD trials in that
participants were allowed to continue concomitant treatment with a
psychostimulant for ADHD, as long as other eligibility criteria for
TADS were met, and the psychostimulant’s dose had been stable
(25% change in dose) during the preceding 6 months. The com-
munity-prescribing clinician ceded control of the psychostimulant
treatment to the TADS pharmacotherapist if the adolescent was
assigned to a pharmacological treatment condition, whereas the
community clinician continued treatment management if assigned
to CBT alone (TADS 2003). The TADS protocol and procedures
were approved by each site’s local Institutional Review Board, and
a National Institute of Mental Health (NIMH) Data and Safety
Monitoring Board monitored the study. Written parental consent
and written participant assent were obtained for all subjects (TADS
2003; TADS 2005).
The diagnoses ofMDD and co-morbid conditions for current and
past episodes were established prior to randomization using the
Schedule for Affective Disorders and Schizophrenia for School-
Age Children–Present and Lifetime Version (K-SADS-PL)
(Kaufman et al. 1997). Of the 439 enrolled participants in TADS,
60 met current Diagnostic and Statistical Manual of Mental Dis-
orders, 4th edition (DSM-IV) (American Psychiatric Association
1994) criteria for ADHD, of any subtype. Two additional partici-
pants were included in our sample that had a history of ADHD and
were currently taking a psychostimulant for ADHD, but did not
have a current diagnosis of ADHD. For the purpose of this manu-
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script, 62 (14.1%) TADS participants were identified as having
ADHD, including 20 participants (32.3% of the ADHD sample)
who had been taking a stable dose of a psychostimulant for ADHD
at study entry.
Primary outcome measure
The primary outcome measure for our analyses was the Chil-
dren’s Depression Rating Scale–Revised (CDRS-R) clinician-
based total scores at baseline evaluation and as reassessed each 6
weeks until the end of acute treatment at week 12 and end of the
study treatment at week 36. The CDRS-R is a 17-item measure of
depression severity over the past week that was administered by an
independent evaluator, an experienced clinician who was masked
as to the adolescent’s assigned treatment. Separate adolescent and
parent interviews were completed to yield a clinician summary
score, ranging from 17 to 113, with higher scores representing more
severe depression. The scale has good internal consistency (coef-
ficient alpha¼ 0.85), interrater reliability (r¼ 0.92), test–retest
reliability (r¼ 0.78), and is correlated with a range of validity in-
dicators, including global ratings and a diagnosis of depression
(Poznanski and Mokros 1995). A score of 45 or greater (indicating
at least moderate clinical depression) was required for TADS study
entry. At TADS baseline, the CDRS-R total scores ranged from 45
to 98 (mean 60, standard deviation [SD]¼ 10.4), which translates
to a normed T-score of 75.5 (SD¼ 6.43), indicating moderate to
moderately severe depression (TADS 2005).
Baseline indicators
Several clinical indicators were used in these analyses to ex-
amine differences among the subgroups’ characteristics at study
entry. Psychometric properties and intercorrelations for these
measures are acceptable and have been reported in prior publica-
tions (TADS 2003; TADS 2005). The Reynolds Adolescent De-
pression Scale (RADS) (Reynolds 1987a) is a 30-item adolescent
report of depression severity over the past month, with a total score
ranging from 30 to 150. In TADS, more than half (58.9%) of par-
ticipants had a total score of77 at baseline, indicating moderately
severe clinical depression, whereas 19.6% had a total score indi-
cating severe to extreme clinical depression (TADS 2005). Suicidal
ideation over the past month was measured by a 15-item subscale of
the Suicidal Ideation Questionnaire–Junior High School Version
(SIQ-Jr) (Reynolds 1987b). A cutoff score of 31 generally indi-
cates suicidal ideation of sufficient severity to warrant prompt
clinical evaluation and is used in this analysis. At baseline, 30.3%
of participants met this flag criterion on the SIQ-Jr. The 100-point
Children’s Global Assessment Scale (CGAS) (Shaffer et al. 1983)
is a clinician rating of general functioning over the past week, with
higher scores indicating better functioning.
The Conners’ Parent Rating Scale–Revised: Long Version
(CPRS-R:L) (Conners 1997) is an 80-item parent rating of ADHD
symptoms and other problem behaviors. Total subscale scores are
converted into normed T-scores, with 66–70 considered moder-
ately atypical, and>70 considered atypical. CPRS-R:L subscale T-
scores used in this analysis include: Oppositional, hyperactivity,
cognitive problems, ADHD index, global index, and DSM-IV total
symptoms, which is further divided into DSM-IV Inattentive
symptoms and DSM-IV Hyperactivity=Impulsivity symptoms. The
ADHD index is a set of items found useful for identifying ‘‘at-risk’’
youth for ADHD, whereas the Conners global index repre-
sents overall psychopathology, loading on two factors: Restless=
impulsivity and emotional lability (Conners 1997).
Premature termination and study dropout
TADS (2003) defined premature termination as having dis-
continued assigned study treatment to begin an out-of-protocol
treatment, while continuing to participate in study assessments
conducted every 6 weeks. The decision to terminate treatment
prematurely was based solely upon the clinician’s recommendation
and not due to mere lack of response or treatment preference. A
study dropout was defined as having withdrawn consent or having
discontinued assigned treatment and study assessments.
Statistical analyses
Descriptive statistics were used to summarize sample charac-
teristics. Frequencies and percentages summarized categorical
data, whereas means (SD) summarized continuous data. All ana-
lyses were conducted using SAS 8.2 (SAS Institute 2002). Due to
the exploratory nature of the analysis, statistical significance was
set at p¼ 0.05 for each nondirectional test. The two ADHD sub-
groups (MDD with and without ADHD) were compared on key
demographic and clinical indicators prior to initiation of treatment.
Fisher exact tests were employed for binary measures because
some comparisons had small cell sizes, and Student t-tests were
used for continuous measures. Chi-squared tests were used to test
for differences in the proportion of youths randomized to each
treatment condition within the two ADHD subgroups.
By definition, a moderator of treatment outcome is a pretreat-
ment variable that is not correlated with treatment, but interacts
with treatment resulting in a different profile of treatment effects
within the moderator subgroups. A nonspecific predictor of out-
come, on the other hand, is a pretreatment variable that is not
associated with treatment but significantly influences outcome re-
gardless of treatment condition.
We conducted two intent-to-treat (ITT) analyses on the CDRS-R
total scores collected across assessments to determine whether the
ADHD diagnosis was a nonspecific predictor or moderator of
treatment outcome across 12 weeks of acute treatment and 36
weeks. This analysis was conducted using the methodological ap-
proach recommended by Kraemer and colleagues (2002), and was
the same analytic approach applied in the primary efficacy analysis
of TADS (TADS 2004; TADS 2007), with the exception that the
overall analyses incorporated the ADHD subgroup and its inter-
actions tested whether ADHD influenced outcome over 12 weeks
and=or 36 weeks.
Longitudinal analyses of the CDRS-R total score were con-
ducted with random coefficients regression models (RRM) (Brown
and Prescott 1999) to compare the short-term outcome of four
treatments during the initial 12-week acute treatment period and the
long-term outcome across 36 weeks of the three active treatments
(e.g., COMB, FLX, and CBT). The PBO treatment armwas omitted
in the longer-term week-36 analysis due to the discontinuation of
PBO after 12 weeks. The ITT analyses included all enrolled par-
ticipants in the treatment groups to which they were randomly
assigned, regardless of their protocol adherence, actual treatment
received, and=or subsequent withdrawal or deviation from the
protocol. The overall RRM model for the week-12 and week-36
analyses included the: (1) Fixed effects of site, treatment, time,
treatment-by-time, ADHD subgroup, and its two- and three-way
interactions, and (2) random effects of participant and participant-
by-time on the CDRS-R total score. Site was retained in the model
as a covariate because treatments were nested within site and time
was defined as the natural log of time þ 1 (measured as days since
randomization). Although the temporal effects were significantly
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linear over the initial 12 weeks, the relationship was quadratic
(nonlinear) over the 36 weeks. Thus, the final analysis model for the
initial 12 weeks was a hierarchical linear mixed model, whereas the
week-36 data was analyzed using a hierarchical quadratic mixed
model.
For the 439 depressed adolescents included in the week-12
analysis, the two subgroups included youths diagnosed with ADHD
(n¼ 62) and without ADHD (n¼ 377). Because the PBO arm was
omitted from the week-36 analysis, the sample of 327 included a
smaller number of youths with ADHD (n¼ 43) and without ADHD
(n¼ 284). If the above omnibus model indicated a significant
ADHD-by-treatment or ADHD-by-treatment-by-time interaction,
then a separate RRM for each ADHD subgroup was conducted to
examine the fixed effects of site, treatment, treatment-by-time, as
well the random effects of participant and participant-by-time. For
each conducted RRM that resulted in a significant treatment or
treatment-by-time effect ( p 0.05), a posteriori paired contrasts
were conducted to examine treatment differences.
For the 62 youths in the ADHD subgroup, we also conducted a
24 analysis of variance using a general linear model approach to
examine the effects of stimulant medication use and treatment as-
signment and interaction on CDRS-R total scores at baseline. For
this analysis, we included the subgroup of depressed adolescents
with ADHD who, at baseline, were currently treated with a stim-
ulant medication (n¼ 20) and those untreated for ADHD (n¼ 42).
Results
Of the 439 enrolled adolescent participants in TADS, 62 (14.1%)
were assessed as having a diagnosis of ADHD at study entry. TADS
participants with ADHD had a mean age of 14.6 (SD 1.5) years at
time of consent. There were twice as many males (66.1%) as fe-
males ( p< 0.004) in our sample of depressed adolescents who had
a diagnosis of co-morbid ADHD. No difference was found in as-
signed treatment among participants who did or did not have a
diagnosis of ADHD (w2¼ 1.10, p¼ 0.777). Among the 62 youths
with ADHD, 14 (22.6%) were assigned to CBT, 14 (22.6%) as-
signed to FLX, 15 (24.2%) to COMB, and 19 (30.6%) to PBO.
Table 1 presents baseline demographic and clinical indicators for
the subgroups of TADS participants who did or did not have a co-
morbid diagnosis of ADHD at study entry and who were included
in the week-12 analysis.
Mean (SD) for T-scores on the CPRS-R:L subscales, measuring
parent-reported ADHD symptoms and other problem behaviors, are
presented in Table 2.
Premature termination and study dropout
There was no statistical difference ( p¼ 0.999) among partici-
pants with or without a diagnosis of ADHD who prematurely ter-
minated their assigned treatment by week 12, after a TADS
clinician recommended an out-of-protocol treatment, including 6
(9.7%) with ADHD and 36 (9.6%) without ADHD. Furthermore,
there was no significant difference found in the rate of study
dropout at end of the 12-week acute treatment ( p¼ 0.378), in-
cluding 9 (14.5%) with ADHD and 39 (10.3%) without ADHD.
Additionally, there was no significant difference ( p¼ 0.755) found
in the rate of dropout for the overall 36-week treatment among
participants with or without a diagnosis of ADHD, including 17
(27.4%) youths with ADHD and 96 (25.5%) without ADHD who
dropped out of TADS.
12-Week blinded treatment outcome (N¼ 439)
The overall linear RRM completed for the 439 enrolled partic-
ipants over the 12-week acute blinded-treatment period indicated a
significant site effect (F(12, 422)¼ 1.78; p¼ 0.050), linear time ef-
fect (F(1,422)¼ 457.92; p< 0.001), treatment-by-time interaction
(F(3,421)¼ 3.38; p¼ 0.018), and ADHD-by-treatment-by-time in-
teraction (F(3,421¼ 3.11; p¼ 0.026), with the remaining fixed ef-
fects nonsignificant ( p> 0.050). The significant ADHD interaction
demonstrated that improvement in depression was moderated by
ADHD status prior to treatment or having a diagnosis of ADHD
prior to study entry. A separate RRM was then completed for each
ADHD subgroup and showed that each subgroup had a significant
time (without ADHD: F(5,355)¼ 945.58; p 0.001; with ADHD:
F(1,53)¼ 145.18; p< 0.001) and treatment-by-time interaction
(without ADHD: F(3,355)¼ 9.55; p< 0.001; ADHD: F(3,53)¼ 3.03;
p¼ 0.038) effects.
Table 1. Baseline Indicators of Depressed Adolescents with and without ADHD
TADS youth with ADHD n¼ 62 Without ADHD n¼ 377 p value
Gender (male) n (%) 41 (66.13%) 159 (42.18%) <0.005
Caucasian n (%) 50 (80.65%) 274 (72.68%) 0.214
Initial depressive episode n (%) 50 (81.97%) 319 (86.68%) 0.322
Depression severity (CDRS-R total) Mean (SD) 57.58 (9.87) 60.52 (10.43) 0.030
Adolescent-reported MDD (RADS total) Mean (SD) 74.46 (12.61) 80.01 (14.48) 0.003
Global functioning (CGAS rating) Mean (SD) 50.05 (7.70) 49.57 (07.44) 0.690
Potential risk of suicidality flag (SIQ-Jr) n (%) 14 (23.73%) 111 (30.08%) 0.358
Current dysthymia disorder n (%) 11 (17.74%) 35 (9.31%) 0.070
Current anxiety disorder n (%) 12 (19.35%) 108 (28.72%) 0.166
Current oppositional defiant disorder n (%) 18 (29.03%) 40 (10.61%) <0.001
Current substance abuse disorder n (%) 1 (1.61%) 6 (1.59%) 1.000
Current alcohol abuse disorder n (%) 1 (1.61%) 2 (0.53%) 0.358
Table’s values are expressed as n¼ number of randomized participants (percentage [%]), or as a group mean (standard deviation [SD]). For mean data,
p values represent the Fisher exact tests for binary measures and Student t-tests for continuous measures.
Anxiety disorder includes the diagnoses of panic disorder, separation anxiety disorder, specific phobia, social phobia, agoraphobia, generalized anxiety
disorder, posttraumatic stress disorder, and=or acute stress disorder.
Abbreviations: ADHD¼Attention-deficit=hyperactivity disorder; TADS¼Treatment for Adolescents with Depression Study; CDRS-R¼Children’s
Depression Rating Scale–Revised; MDD¼major depressive disorder; RADS¼Reynolds Adolescent Depression Scale; SIQ-Jr¼Suicidal Inventory
Questionnaire–Junior High School Version.
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For the 377 depressed youths in TADS without ADHD, the
profile for the rate of improvement across 12 weeks was: COMB>
(FLX > CBT)¼ PBO. The COMB treatment condition had a sig-
nificantly faster average trajectory of change across 12 weeks
( p< 0.009) relative to FLX, CBT, or PBO. Neither FLX
( p¼ 0.425) nor CBT ( p¼ 0.065) was significantly different than
PBO in terms of rate of improvement, although FLX ( p¼ 0.008)
had a significantly greater average improvement rate compared to
CBT, indicating that CBT had the most gradual improvement tra-
jectory among the active treatments.
A different pattern of treatment effects was observed for the 62
depressed youths with ADHD, which was (CBT¼ FLX¼COMB)
> PBO. Compared to PBO, the treatment conditions of CBT
( p¼ 0.013), FLX ( p¼ 0.024), and COMB ( p¼ 0.046) showed
significantly greater average rates of improvement during the 12-
week blinded treatment. None of the three active treatments was
significantly different in terms of their change trajectories (all
p> 0.050).
Improvement, as measured by lower mean CDRS-R scores, was
observed in all four treatment conditions of both subgroups over the
12-week blinded-treatment period, which included three assess-
ment visits at baseline and at weeks 6 and 12. The mean CDRS-R
scores over the 12-week period, adjusted for the fixed and random
effects in the analytic model, are presented in Table 3 for the two
ADHD subgroups, and presented graphically in Fig. 1.
The CGI-I response rate at week 12, using last observation
carried forward (LOCF) when a score was missing, was 53.3% for
the youths without ADHD and 45.2% for those with ADHD
(chi¼ 1.4, degrees of freedom [df]¼ 1, p¼ 0.230, effect size¼
0.2). Table 4 presents the between-treatment effect sizes at week 12
for the two subgroups of depressed adolescents, with and without
ADHD.
36-week treatment outcome (N¼ 327)
The analysis, which included an adjustment for a significant
quadratic temporal relationship (time2) of the three active treatment
conditions and the CDRS-R total scores across 36 weeks, also
demonstrated a moderator effect for ADHD status. The overall
analysis demonstrated a significant time (F(1,1456)¼ 45.59; p<
0.001), ADHD-by-time2 (quadratic) interaction (F(1,1298¼ 5.04;
p¼ 0.025), ADHD-by-treatment-by time interaction (F(2,145)¼
5.60; p¼ 0.004), and ADHD-by-treatment-by-time2 interaction
(F(2,1297¼ 5.53; p¼ 0.004), while the remaining fixed effects were
nonsignificant (all p< 0.050). The significant ADHD-by-treat-
ment-by-time2 interaction demonstrated that having a diagnosis of
ADHD had a moderating effect during the 36-week treatment
period.
For the 284 youths without ADHD, there was a significant
treatment-by-time2 interaction (F(2,1127)¼ 23.56; p< 0.001) in
which there was a significant difference in the improvement trajec-
tory of this subgroup. As during the initial 12 weeks, the most rapid
rate of improvement was observed in the COMB condition (all
p> 0.050), which was significantly different from CBT and FLX in
terms of trajectories, with CBT having a significantly more gradual
improvement over the 36 weeks relative to COMB and FLX. Paired
Table 2. Conners’ Parent Rating Scale–Revised Subscale T-Scores
Youth With ADHD n¼ 62 Without ADHD n¼ 377 t-Value p Value
Oppositional subscale 74.62 (10.89) 70.05 (13.25) ÿ2.87 0.005
Cognitive problems subscale 76.35 (09.25) 67.57 (11.95) ÿ4.51 <0.001
Hyperactivity subscale 77.41 (15.56) 62.55 (14.91) ÿ5.44 <0.001
ADHD index 78.57 (08.71) 67.81 (11.68) ÿ7.25 <0.001
Conners’ Global Index 80.23 (11.38) 71.01 (13.03) ÿ4.51 <0.001
DSM-IV Total Symptoms 80.54 (9.99) 67.33 (12.37) ÿ7.88 <0.001
DSM-IV Inattention Symptoms 78.40 (08.88) 68.20 (12.25) ÿ6.73 <0.001
DSM-IV Hyperactivity=Impulsivity 77.06 (15.62) 60.89 (13.35) ÿ6.01 <0.001
Conners’ Parent Rating Scale, Revised-Long Version subscale values are expressed as T-score group means and standard deviation (SD) at baseline.
p values are for Student t-tests. ADHD Index subscale consists of items useful for identifying ‘‘at risk’’ youth for ADHD. Global Index measures
psychopathology of two factors: Restless=impulsivity and emotional lability. DSM-IV Total Symptoms subscale items match to diagnostic criteria of
combined subtype of ADHD, while DSM-IV Inattention Symptoms subscale matches to inattentive subtype of ADHD, and DSM-IV
Hyperactivity=Impulsivity subscale matches to ADHD subtype.
Abbreviations: ADHD¼Attention-deficit=hyperactivity disorder; DSM-IV¼Diagnostic and Statistical Manual of Mental Disorders, 4th edition.
Table 3. Mean Adjusted CDRS-R Total Scores for the 12-Week Analysis (N¼ 439)
Fluoxetine alone CBT alone Combination (CBTþ fluoxetine) Pill placebo
Youth with
ADHD
n¼ 14
Without
ADHD
n¼ 95
Youth with
ADHD
n¼ 14
Without
ADHD
n¼ 97
Youth with
ADHD
n¼ 15
Without
ADHD
n¼ 92
Youth with
ADHD
n¼ 19
Without
ADHD
n¼ 93
Baseline 56.08 3.93 59.36 4.24 60.01 4.66 59.59 4.78 58.59 7.33 61.14 4.78 55.55 4.50 62.33 4.43
Week 6 37.05 6.03 40.37 7.33 39.45 5.68 44.98 8.22 40.73 8.54 37.58 7.67 45.25 5.30 44.59 7.42
Week 12 33.29 6.42 36.83 8.11 35.95 6.34 42.35 8.96 37.08 9.42 33.30 8.14 43.31 5.65 41.39 8.07
Mean adjusted scores derived from the subgroup analyses.
Abbreviations: CDRS-R¼Children’s Depression Rating Scale–Revised; ADHD¼ attention-deficit=hyperactivity disorder; CBT¼ cognitive–behavioral
therapy.
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contrasts of mean CDRS-R scores were conducted at week 36 to test
for between-treatment differences within each ADHD subgroup. No
significant difference was found among any of the active treatment
groups in terms of their mean CDRS-R scores.
The ADHD subgroup (n¼ 43) analysis did not demonstrate any
significant treatment-by-time2 or treatment-by-time interactions.
To examine between-treatment differences in light of the small
sample size per treatment condition, exploratory paired contrasts
were conducted in the absence of a significant treatment-by-time2
interaction within this subgroup. As expected, there were no sig-
nificant differences in change trajectories or in CDRS-R total
scores at week 36 (all p> 0.050). The separate RRM analysis for
each ADHD subgroup revealed the following, as depicted in Fig. 2.
CGI-I response rate at week 36, using LOCF when a score was
missing, was 75.4% for the youths without ADHD and 62.8% with
ADHD (chi¼ 3.0, df¼ 1, p¼ 0.080).
Psychostimulant treatment of ADHD
At time of randomization to TADS treatment, 20 (32.2%) of the
62 depressed adolescents who were diagnosed with ADHD were
taking a stimulant medication to treat ADHD. Our analysis showed
that CDRS-R depression scores did not prove to be significantly
different for the group of 20 youths treated with a psychostimulant,
as compared to the group of 43 youths who were not treated for
ADHD (F(1,54)¼ 0.34, p¼ 0.056). Additionally, no significant
treatment-by-psychostimulant use interaction was found
( p> 0.050).
Discussion
This analysis examines the impact of having a co-morbid diag-
nosis of ADHD on the outcome of treatment for depression in
FIG. 1. CDRS-R adjusted total scores for youths with and
without ADHD across the 12-week analysis. Shown is the profile
of treatment-group effects based on the hierarchical linear mixed
regression models completed to compare the outcome of four
treatments during the initial 12 weeks. CDRS-R¼Children’s
Depression Rating Scale–Revised; ADHD¼ attention-deficit=
hyperactivity disorder; COMB¼ combined treatment of cogni-
tive–behavioral therapy and fluoxetine; FLX¼ fluoxetine;
CBT¼ cognitive–behavioral therapy; PBO¼ pill placebo.
Table 4. Between-Treatment Effect Sizes at Week 12
for Adolescents, with and without ADHD
Treatment comparison
Youths
without ADHD
Youths
with ADHD
Active treatment versus PBO
COMB versus PBO 1.0 0.8
FLX versus PBO 0.6 1.7
CBT versus PBO ÿ0.1 1.2
Abbreviations: ADHD¼Attention-deficit=hyperactivity disorder; PBO¼
pill placebo; COMB¼ combinational treatment with cognitive–behavioral
therapy plus fluoxetine; FLX¼fluoxetine; CBT¼ cognitive–behavioral
therapy.
FIG. 2. CDRS-R adjusted total scores for youths with and
without ADHD across the 36-week analysis. Shown is the profile
of treatment-group effects based on the random coefficients re-
gression models completed to compare the outcome of three
treatments across 36 weeks. CDRS-R¼Children’s Depression
Rating Scale–Revised; ADHD¼ attention-deficit=hyperactivity
disorder; COMB¼ combined treatment of cognitive–behavioral
therapy and fluoxetine; FLX¼ fluoxetine; CBT¼ cognitive–
behavioral therapy.
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adolescents who participated in TADS. Approximately one in
seven (14.1%) adolescent participants met criteria for a diagnosis
of ADHD. As hypothesized, ADHD was a moderator of treatment
response. We found a differential response to TADS treatment in
the depressed youths with a co-morbid diagnosis of ADHD, as
compared to without ADHD. The ADHD subgroup analyses pre-
sented in this paper are exploratory in nature, due to the limited
number of youths in TADS with ADHD, which affects the statis-
tical power to detect significant differences between the subgroups
and increases the possibility of Type II errors (i.e., false negatives).
Although our expectation that depressed adolescent participants
with ADHD would have a less robust response to treatment than
those without ADHD was not met, our prediction of a differential
response moderated by having a diagnosis of ADHD was sup-
ported. In TADS youths who had ADHD, the three treatment
groups of COMB, FLX, and CBT had a similarly greater average
rate of improvement during the 12-week blinded treatment com-
pared to PBO. This rate of improvement similarly continued during
the remaining 24 weeks of the study for all three active treatments.
This is a different trajectory, based on rate of improvement, com-
pared to the group of depressed adolescents in TADS who did not
have ADHD.
In our analysis of youths without ADHD, the COMB treatment
group experienced the greatest rate of improvement during the
initial 12 weeks, with COMB superior to PBO. CBT continued to
have a more gradual rate of improvement over the 36-week period
compared to COMB or FLX. By end of treatment at week 36, all
active treatments were similarly effective in alleviating depressive
symptoms in TADS youths, regardless of whether or not they had
ADHD.
Our secondary hypothesis—that participants with ADHD would
prematurely terminate their assigned treatment and drop out of the
study more often than participants without ADHD—was not sup-
ported. We found no significant difference between the youths with
or without ADHD in the rate of study dropout or premature ter-
mination (i.e., study treatment stopped due to starting a clinician-
recommended nonprotocol treatment). Finally, our hypothesis that
ADHD youths would have higher global impairment and higher
level of suicidality compared to youths without ADHDwas also not
supported. Instead we found that as a group ADHD youths did not
differ from those without ADHD in their overall global impairment
or their level of suicidality. In fact, althought we predicted a higher
severity ofMDD in the ADHD youths, we found that ADHD youths
in the TADS sample had significantly less severe depressive
symptoms at baseline than those without ADHD, on both the cli-
nician-administered CDRS-R and on the adolescent-completed
RADS. Additionally, there was no difference between those ado-
lescents with and those without ADHD in the age of onset of MDD,
duration of MDD episode, or rate of recurrent depression (all
p> 0.050). There was, however, an increased rate of concurrent
dysthymia in those with ADHD (17.7% vs. 9.3%; p¼ 0.0448).
We speculate regarding possible reasons for these differing re-
sults, particularly that CBT had a superior trajectory of improve-
ment over PBO in youths with ADHD, but not for those without
ADHD. We initially believed that depressed youths with ADHD
would benefit less from CBT due to the cognitive deficits of ADHD
and the cognitive requirements in CBT, such as completing and
applying homework-based concepts. In TADS, parents of ADHD
youths typically described their teens as experiencing significant
levels of inattention, hyperactivity, impulsivity, and emotional la-
bility, in addition to their depression. Despite the elevated levels of
ADHD symptoms, CBT, as offered in TADS, provided an inter-
vention that was particularly beneficial for the depressed adoles-
cents with ADHD. It is possible that the CBT in TADS overlaps
with interventions having demonstrated efficacy in the treatment of
ADHD in children (Birmaher et al. 1996; Lewinsohn et al. 1999;
MTA Cooperative Group 1999), such as goal setting, problem
solving, charting of affect regulation, and contingency manage-
ment. Unfortunately, data on the role of CBT per se in the treatment
of ADHD in children and adolescents are more limited than other
psychosocial interventions, with seminal studies like the MTA
focusing on behavioral interventions rather than CBT.
As the largest study of adolescent depression completed to date,
TADS is one of the few pediatric depression studies with a design
and size adequate to investigate beyond primary comparative out-
comes. Unfortunately, our exploratory analysis of the 62 youths in
TADS who had a co-morbid diagnosis of ADHD is still quite
limited in size, which limits the generalizability of our results. If
replicated in future studies, our findings could strengthen guidance
in the treatment of adolescents with co-morbid MDD and ADHD.
In particular, our findings would suggest that any of the three TADS
interventions of CBT, FLX, or COMBmay be an appropriate initial
treatment for depression in an adolescent with co-morbid depres-
sion and ADHD. The treatment recommendations must be indi-
vidualized, however, taking into consideration other possible
clinical concerns, co-morbidities, treatment availability, and family
preference,
All three active treatment groups had an average decrease in
mean CDRS-R score of greater than 20 points at week 12, yet
slightly less than half of the co-morbid youths reachedmuch or very
much improvement after 3 months of treatment, suggesting the
need for better treatments for depression, particularly with co-
morbid ADHD. Further examination of the role of concomitant
ADHD pharmacotherapy during treatment of adolescent depres-
sion might prove clinically invaluable, but this is well beyond the
feasibility of our subsample of 20 youths who were treated with a
stimulant medication. We recommend conducting larger studies
that are more adequately powered to examine moderator and me-
diator analyses, which are needed to better guide clinical treatment
of common co-morbidities in adolescents.
TADS was unique among pediatric MDD trials in allowing
depressed adolescents with co-morbidities such as ADHD to con-
tinue taking daily treatment with a psychostimulant. By allowing
such real-world aspects in a controlled study, data such as this
become increasingly relevant to clinical practice. In our analyses,
ADHD moderated the short- and longer-term effects of MDD
treatment in youths with co-morbid ADHD compared to without
ADHD. Our findings indicated that CBT, COMB, and FLX had
similar improvement trajectories in depressed youths with ADHD,
whereas COMB had superior improvement in youths without
ADHD. Thus, our results suggest that any of these three TADS
interventions of CBT, FLX, or COMBmay be an appropriate initial
treatment of depression in adolescents with co-morbid ADHD.
Disclosures
Dr. Kratochvil has or does receive grant support from Eli Lilly,
Ortho-McNeil, Shire, Abbott, Pfizer, Somerset, Cephalon, and
NIMH; he has been a consultant for Eli Lilly, AstraZeneca, Abbott,
and Pfizer; and he is currently receiving medication at no cost from
Eli Lilly for a study. Ms. May has received grant support from
Shire, Abbott, Somerset, Cephalon, and NIMH. Dr. Silva is a
consultant to Pfizer. Dr. March owns stock in MedAvante and has
been a consultant for Pfizer,Wyeth, Eli Lilly, and GlaxoSmithKline;
TREATMENT RESPONSE IN DEPRESSED ADOLESCENTS WITH ADHD 525
he has received research support from Eli Lilly and has served on
data safety monitoring boards for AstraZeneca and Johnson &
Johnson; he is currently receiving medication at no cost from Pfizer
and Eli Lilly for a study; and he has received royalty payments for
the Multidimensional Anxiety Scale for Children. Dr. Walkup re-
ports receiving consulting fees from Eli Lilly and Jazz Pharma-
ceuticals and fees for legal consultation to defense counsel and
submission of written reports in litigation involving Glaxo-
SmithKline, receiving lecture fees from CMP Media, Medical
Education Reviews, McMahon Group, and DiMedix, and receiving
support in the form of free medication and matching placebo from
Eli Lilly and free medication from Abbott for clinical trials funded
by the NIMH. All other authors have no financial ties or conflicts of
interest to report. Eli Lilly provided fluoxetine and matching pla-
cebo under an independent educational grant to Duke University.
Acknowledgments
The authors would like to thank the members of the Treatment
for Adolescents with Depression Study (TADS) Team. The TADS
is coordinated by the Department of Psychiatry and Behavioral
Sciences and the Duke Clinical Research Institute at Duke Uni-
versity Medical Center, Durham, North Carolina, in collaboration
with the NIMH. The Coordinating Center principal collaborators
are John S. March, Susan Silva, Stephen Petrycki, John Curry,
Karen Wells, John Fairbank, Barbara Burns, Marisa Domino, and
Steven McNulty. The NIMH principal collaborators are Benedetto
Vitiello and Joanne Severe. Principal investigators and coinvesti-
gators from the clinical sites are as follows: Charles Casat, Jeanette
Kolker, and Karyn Riedal (Carolinas Medical Center, Charlotte,
North Carolina); Norah Feeny, Robert Findling, Sheridan Stull, and
Susan Baab (Case Western Reserve University, Cleveland, Ohio);
Elizabeth B. Weller, Michele Robins, Ronald A. Weller, and
Naushad Jessani (The Children’s Hospital of Philadelphia, Phila-
delphia, Pennsylvania); Bruce Waslick (Baystate Health=Tufts
University, Springfield, Massachusetts), Michael Sweeney, and
Randi Dublin (Columbia University, New York, New York); John
Walkup, Golda Ginsburg, Elizabeth Kastelic, and Hyung Koo (The
Johns Hopkins University, Baltimore, Maryland); Christopher
Kratochvil, Diane May, Randy LaGrone, and Brigette Vaughan
(University of Nebraska, Omaha); Anne Marie Albano (Columbia
University), Glenn S. Hirsch, and Elizabeth Podniesinki (NewYork
University, New York); Mark Reinecke, Bennett Leventhal, Gre-
gory Rogers, and Rachel Jacobs (University of Chicago, Chicago,
Illinois, and Northwestern University, Evanston, Illinois); Sanjeev
Pathak, Jennifer Wells, Sarah Arszman, and Arman Danielyan
(Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio);
Paul Rohde, Anne Simons, James Grimm, and Stephenie Frank
(University of Oregon, Eugene); Graham Emslie, Beth Kennard,
Carroll Hughes, and Taryn L. Mayes (The University of Texas
Southwestern Medical Center, Dallas); David Rosenberg, Nili
Benazon, Michael Butkus, and Marla Bartoi (Wayne State Uni-
versity, Detroit, Michigan); and Kelly Posner, for the Columbia
University Suicidality Classification Group. James Rochon (Duke
Clinical Research Institute, Durham) was statistical consultant for
TADS.
References
American Psychiatric Association: Diagnostic and Statistical Manual
of Mental Disorders, 4th edition. (DSM-IV). Washington (DC):
American Psychiatric Association, 1994.
Anderson JC, Williams S, McGee R, Silva PA: DSM-III disorders in
preadolescent children: Prevalence in a large sample from the
general population. Arch Gen Psychiatry 44:69–76, 1987.
Angold A, Costello J, Erkanli A: Comorbidity. J Child Psychol Psy-
chiatry 40:57–87, 1999.
Antshel KM, Barkley R: Psychosocial interventions in attention def-
icit hyperactivity disorder. Child Adolesc Psychiatr Clin N Am
17:421–437, 2008.
Atomoxetine ADHD and Comorbid MDD Study Group: Bangs ME,
Emslie GE, Spencer TJ, Ramsey JL, Carlson C, Bartky EJ, Busner
J, Duesenberg DA, Harshawat P, Kaplan SL, Quintana H, Allen AJ,
Sumner CR: Efficacy and safety of atomoxetine in adolescents with
ADHD and major depression. J Child Adolesc Psychopharmacol
17:407–420, 2007.
Barrickman L, Noyes R, Kuperman S, Schumacher E, Verda M:
Treatment of ADHD with fluoxetine: A preliminary trial. J Am
Acad Child Adolesc Psychiatry 30:762–767, 1991.
Biederman J, Newcorn J, Sprich S: Comorbidity of attention deficit
hyperactivity disorder with conduct, depressive, anxiety, and other
disorders. Am J Psychiatry 148:564–577, 1991.
Biederman J, Baldessarini RJ, Wright V, Keenan K, Faraone S: A
double-blind placebo controlled study of desipramine in the treat-
ment of ADD: III. Lack of impact of comorbidity and family his-
tory factors on clinical response. J Am Acad Child Adolesc
Psychiatry 32:199–204, 1993.
Biederman J, Ball S, Monuteaux M, Mick E, Spencer T, McCreary M,
Cote M, Farone S: New insights into the comorbidity between
ADHD and major depression in adolescent and young adult fe-
males. J Am Acad Child Adolesc Psychiatry 47:426–434, 2008.
Birmaher B, Ryan ND, Williamson DE, Brent DA, Kaufman J, Dahl
RE, Perel J, Nelson B: Childhood and adolescent depression: A
review of the past 10 years, Part I. J Am Acad Child Adolesc
Psychiatry 35:1427–1439, 1996.
Conners CK: Technical Manual for the Conners’ Rating Scales-
Revised. North Tonawanda (New York): Multi-Health Systems,
1997.
Daviss WB, Bentivoglio P, Racusin R, Brown KM, Bostic JQ, Wiley
L: Bupropion sustained release in adolescents with comorbid
attention-deficit=hyperactivity disorder and depression. J Am Acad
Child Adolesc Psychiatry 40:307–314, 2001.
Findling RL: Open-label treatment of comorbid depression and at-
tentional disorders with co-administration of serotonin reuptake
inhibitors and psychostimulants in children, adolescents, and adults:
A case series. J Child Adolesc Psychopharmacol 6:165–175, 1996.
Geller B, Reising D, Leonard HL, Riddle MA, Walsh BT: Critical
review of tricyclic antidepressant use in children and adolescents.
J Am Acad Child Adolesc Psychiatry 38:513–516, 1999.
Goldstein BJ, Goodnick PJ. Selective serotonin reuptake inhibitors in
the treatment of affective disorders. III. Tolerability, safety and
pharmacoeconomics. J Psychopharmacol 12(3 Suppl B):S55–S87,
1998.
Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, Wil-
liamson D, Ryan N: Schedule for Affective Disorders and Schi-
zophrenia for School-Age Children-Present and Lifetime Version
(K-SADS-PL): Initial reliability and validity data. J Am Acad Child
Adolesc Psychiatry 36:980–988, 1997.
Kraemer HC, Wilson GT, Fairburn CG, Agras WS: Mediators and
moderators of treatment effects in randomized clinical trials. Arch
Gen Psychiatry 59:877–883, 2002.
Kratochvil CJ, Newcorn JH, Arnold LE, Duesenberg D, Emslie GJ,
Quintana H, Sarkis EH, Wagner KD, Gao H, Michelson D, Bie-
derman J: Atomoxetine alone or combined with fluoxetine for
treating ADHD with comorbid depressive or anxiety symptoms.
J Am Acad Child Adolesc Psychiatry 44:915–924, 2005.
526 KRATOCHVIL ET AL.
Lewinsohn PM, Clarke GN: Psychosocial treatments for adolescent
depression. ClinPsychol Rev 19:329–342, 1999.
MTA Cooperative Group: A 14-month randomized clinical trial
of treatment strategies for attention-deficit=hyperactivity disor-
der. The MTA Cooperative Group. Multimodal Treatment Study
of Children with ADHD. Arch Gen Psychiatry 56:1073–1086,
1999.
Mufson L, Sills R: Interpersonal Psychotherapy for depressed ado-
lescents (IPT-A): An overview. Nord J Psychiatry 60:431–437,
2006.
Quintana H, Butterbaugh GJ, Purnell W, Layman AK: Fluoxetine
monotherapy in attention-deficit=hyperactivity disorder and co-
morbid non-bipolar mood disorders in children and adolescents.
Child Psychiatry Hum Dev 37:241–253, 2007.
Poznanski EO, Mokros HB: Children’s Depression Rating Scale-
Revised Manual. Los Angeles (California): Western Psychological
Services, 1995.
Prince JB, Wilens TE, Biederman J, Spencer TJ, Millstein R, Polisner
DA, Bostic JQ: A controlled study of nortriptyline in children and
adolescents with attention deficit hyperactivity disorder. J Child
Adolesc Psychopharmacol 10:193–204, 2000.
Reinecke MA, Ryan NE, Dubois DL: Cognitive-behavioral therapy of
depression and depressive symptoms during adolescence: A review
and meta-analysis. J Am Acad Child Adolesc Psychiatry 37:26–34,
1998.
Reynolds WM: Professional Manual for the Reynolds Adolescent
Depression Scale. Odessa (Florida): Psychological Assessment
Resources, 1987a.
Reynolds WM: Professional Manual for the Suicidal Ideation Ques-
tionnaire. Lutz (Florida): Psychological Assessment Resources,
1987b.
SAS Institute, SAS System for Windows, version 8.2. Cary (North
Carolina): SAS Institute, 2002.
Shaffer D, Gould MS, Brasic J, Ambrosini P, Fisher P, Bird H,
Aluwahlia S: A children’s global assessment scale (CGAS). Arch
Gen Psychiatry 40:1228–1231, 1983.
Stoll AL, Pillay SS, Diamond L, Workum SB, Cole JO: Methylphe-
nidate augmentation of serotonin selective reuptake inhibitors: A
case series. J Clin Psychiatry 57:72–76, 1996.
The Treatment for Adolescents with Depression Study (TADS) Team:
Treatment for Adolescents with Depression Study (TADS): Ratio-
nale, design, and methods. J Am Acad Child Adolesc Psychiatry
42:531–542, 2003.
The Treatment for Adolescents with Depression Study (TADS) Team:
Fluoxetine, cognitive-behavioral therapy, and their combination for
adolescents with depression: Treatment for Adolescents with De-
pression Study (TADS) randomized controlled trial. JAMA
292:807–820, 2004.
The Treatment for Adolescents with Depression Study (TADS) Team:
The Treatment for Adolescents with Depression Study (TADS):
Demographics and clinical characteristics. J Am Acad Child Ado-
lesc Psychiatry 44:28–40, 2005.
The Treatment for Adolescents with Depression Study (TADS) Team:
The Treatment for Adolescents with Depression Study (TADS):
Long-term effectiveness and safety outcomes. Arch Gen Psychiatry
64:1132–1144, 2007.
Wilens TE, Biederman J, Geist DE, Steingard R, Spencer T: Nor-
triptyline in the treatment of ADHD: A chart review of 58 cases.
J Am Acad Child Adolesc Psychiatry 32:343–349, 1993.
Address correspondence to:
Christopher J. Kratochvil, M.D.
985581 Nebraska Medical Center
Omaha, NE 68198-5581
E-mail: ckratoch@unmc.edu
TREATMENT RESPONSE IN DEPRESSED ADOLESCENTS WITH ADHD 527

